Working with companies that manufacture breastmilk substitutes: An EAACI position paper

Stefania Arasi, Jean Christoph Caubet, Ozlem Ceylan, Ibon Eguíluz-Gracia, Stefano Del Giacco, Aslı Gelincik, Marek Jutel, Rosan Meyer, Markus Ollert, Maria J. Torres*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review


Breastmilk is the optimal source of nutrition for infants and should ideally be provided exclusively for the first 6 months of life, and alongside complementary food until 2 years of life. However, there are circumstances where a breastmilk substitute (BMS) may be required. This includes maternal and/or child conditions or personal preference. Whilst these circumstances should never be used as an opportunity to promote BMS, healthcare professionals (HCPs) need to have the knowledge of suitable alternatives and should always be guided by scientific and health motives when recommending a BMS. The Task Force ‘Milk Formula Industry Sponsorship’ from the European Academy of Allergy and Clinical Immunology (EAACI), provides with this publication recommendations for EAACI interactions with the BMS manufacturers and how this will be supervised.

Original languageEnglish
Article numbere14142
JournalPediatric Allergy and Immunology
Issue number5
Publication statusPublished - May 2024


  • breastmilk
  • breastmilk substitutes
  • feed for special medical purpose
  • food allergy
  • industry


Dive into the research topics of 'Working with companies that manufacture breastmilk substitutes: An EAACI position paper'. Together they form a unique fingerprint.

Cite this